Yamaguchi University

Cytlimic Inc.

Toyo Kohan Co., Ltd.

Nec Corporation

F. Hoffmann-La Roche Ag

Roche Molecular Systems, Inc.

Sony Computer Entertainment Inc.

Roche Diagnostics Gmbh

Masaaki Oka

Shoichi Hazama

Koji Tamada

Tomoya Miyakawa

Keiko Udaka

Yoshihiko Hamamoto

Toshiyuki Hiroi

Hisafumi Okabe

Ryouichi Tsunedomi

Norio Iizuka

Akio Ohba

Masakazu Suzuoki

Osamu Uchinokura

Junichi Awamura

Tsuneyasu Nagatomo

Satoshi Ogawa

Teiji Yutaka

Masayoshi Tanaka

Teruki Kusahara

Toyoshi Okada

Mamoru Hozumi

Shigeru Tamatsukuri

Syouko Satoh

Kiwako Hirohara

Hiroshi Okamura

Shuichi Kamei

Toshiaki Miura

Toyoki Moribe

Naoko Nakazawa

Shouichi Hazama

Horiyuki Ogihara

Mayuko Hosoya

Takao Tamesa

Yasuaki Ohta

Kenji Hamada

Masaki Watanabe

Takahiro Honda

Daisuke Ito

Satoshi Kojima

Kenji Grandcity Shounan-Enoshima 506 Hamada

The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.

HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell

An object of the present invention is to provide a simple and efficient device for predicting a risk of occurrence of a side effect of irinotecan by analyzing a single nucleotide polymorphism in a region encoding a specific gene. The prediction of the risk of the occurrence of a side effect of irinotecan is assisted by analyzing a single nucleotide polymorphism in a region encoding the APCDD1L gene, the R3HCC1 gene, the OR51I2 gene, the MKKS gene, the EDEM3 gene, or the ACOX1 gene which are present on genomic DNA in a biological sample collected from a test subject; or a single nucleotide polymorphism which is in linkage disequilibrium with or genetically linked to the single nucleotide polymorphism, and determining whether the single nucleotide polymorphism is homozygous for a variant type, heterozygous, or homozygous for a wild-type.

Method for assisting prediction of risk of occurrence of side effect of irinotecan

The present invention provides a peptide that includes eight or more consecutive amino acid residues of amino acid sequence of one of Sequence ID Nos. 1 to 12 and that consists of eleven or less amino acid residues.

MUC1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using same

An information processor can logically support prediction based on past statistical information even though the information contains qualitative or non-numerical data. The processor determines whether an input pattern corresponding to an input object (a determination target) belongs to a specific class among multiple classes, based on feature subsets of any combination of a plurality of features, each feature comprises multiple categories. The processor includes a storage storing the input pattern corresponding to the input object and samples corresponding to respective sample objects and a classification determiner determining whether the input pattern belongs to the specific class. The classification determiner calculates a first conditional probability and a second conditional probability based on the number of the samples belonging to each category of the respective features, the first conditional probability is a probability that the data of the input pattern belong to categories corresponding to the respective feature for the specific class, the second conditional probability is a probability that the data of the input pattern belong to categories corresponding to the respective features for a non-specific class which is a class other than the specific class among classes, and the number of the samples is counted for each class based on the feature information on the samples and the class label information on the samples, and determines whether the input pattern belongs to the specific class based on the feature information on the input pattern, the first conditional probability and the second conditional probability.

Information processing device, information processing program, and information processing method

HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell

The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.

Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells

Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells

A buffer composition for hybridization of a target nucleic acid is provided. The nucleic acid can include a nucleotide to be detected with a nucleic acid probe. The probe can contain a nucleotide sequence complementary to the target nucleic acid. The buffer can include a blocking nucleic acid having a nucleotide sequence complementary to a non-target nucleic acid having a nucleotide not to be detected corresponding to the nucleotide to be detected. The buffer composition can suppress non-specific hybridization to the nucleic acid probe even when a non-target nucleic acid is present. The use of the buffer composition can achieve excellent detection efficiency of the target nucleic acid.

Buffer composition for hybridization use, and hybridization method

The present invention provides a novel method for detection of liver cancer. This method detects high-sensitively, high-specifically, simply and accurately liver cancer, especially that in early stage by identifying and/or quantifying methylation on particular genes and/or their DNA fragments in clinical specimens, and by combining said methylated DNA values with existing tumor marker values and/or DNA amounts in blood. This invention also detects a precancerous lesion, detects a risk of recurrence after treatment of liver cancer, detects malignancy of liver cancer and monitors progression of liver cancer with time by the same method. As for particular genes, BASP1 gene, SPINT2 gene, APC gene, CCND2 gene, CFTR gene, RASSF1 gene and SRD5A2 gene are mentioned.

Liver cancer methods and compositions

The present invention relates to a scoring system for the prediction of cancer recurrence by selecting genes and/or proteins whose expression patterns associated with recurrence of cancer, and generating formulae with the selected genes and/or proteins for the prediction of cancer recurrence. The present invention relates to a kit for determining the likelihood of recurrence of cancer, comprising DNA chip, oligonucleotide chip, protein chip, peptides, antibodies, probes and primers that are necessary for effecting DNA microarrays, oligonucleotide microarrays, protein arrays, northern blotting, in situ hybridization, RNase protection assays, western blotting, ELISA assays, reverse transcription polymerase-chain reaction to examine the expression of at least 2, 4, 6, 10, 12 or more genes and/or proteins, that are indicative of cancer recurrence.

Scoring system for the prediction of cancer recurrence

To provide an effective factor extraction system in which samples are generated artificially from a sample group and a virtual sample set is created so that even when the number of sample is relatively small, specific factors can be selected/extracted with high reliability by using the virtual sample set. The effective factor extraction system comprises a section for extracting samples arbitrarily from sample sets and creating a plurality of paired virtual sample sets, a statistical quantity operating section for reading out the feature value held by sample contained in respective virtual sample sets and operating the average value and the variance, a section for operating Fisher ratio from the average value and the variance, and a section for testing significant factors using the operated Fisher ratio.

Method and system of extracting factors using generalized Fisher ratios

A method for determining the risk of adverse effects of irinotecan (CPT-11), a synthetic anticancer drug, by detecting polymorphisms in the TATA box within the promoter region of the UDP-glucuronosyl transferase gene. A kit for detecting the adverse effects of irinotecan containing at least one pair of nucleic acid probes.

Kits and method for determining the risk of adverse effects of irinotecan comprising hybridizing pairs of nucleic acid probes

The present invention relates to a scoring system for the prediction of cancer recurrence. More particularly, the present invention concerns with the selection of genes and/or proteins, and generation of formulae with the selected genes and/or proteins for the prediction of cancer recurrence by measuring the expression of genes and/or proteins of human tumor tissues, and comparing their patterns with those of the gene and/or protein expression of human primary tumors from patients who have cancer recurrence and those who do not have cancer recurrence. The present invention also relates to a kit for performing the method of the present invention comprising DNA chip, oligonucleotide chip, protein chip, peptides, antibodies, probes and primers that are necessary for effecting DNA microarrays, oligonucleotide microarrays, protein arrays, northern blotting, in situ hybridization, RNase protection assays, western blotting, ELISA assays, reverse transcription polymerase-chain reaction (hereinafter referred to as RT-PCR) to examine the expression of at least 2 or more of genes and/or proteins, preferably 4 or more of genes and/or proteins, more preferably 6 or more of genes and/or proteins, and most preferably 12 or more of genes and/or proteins, that are indicative of cancer recurrence.

Growing community of inventors

Yamaguchi, Japan

Masaaki Oka